JPH0437833B2 - - Google Patents

Info

Publication number
JPH0437833B2
JPH0437833B2 JP58166258A JP16625883A JPH0437833B2 JP H0437833 B2 JPH0437833 B2 JP H0437833B2 JP 58166258 A JP58166258 A JP 58166258A JP 16625883 A JP16625883 A JP 16625883A JP H0437833 B2 JPH0437833 B2 JP H0437833B2
Authority
JP
Japan
Prior art keywords
alkyl
pyridine
dihydropyrazolo
methyl
nitrophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58166258A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6056979A (ja
Inventor
Ikuo Adachi
Teruo Yamamori
Motohiko Ueda
Masami Tsutsumiuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to JP58166258A priority Critical patent/JPS6056979A/ja
Priority to US06/641,822 priority patent/US4562256A/en
Priority to GB08421763A priority patent/GB2146326B/en
Priority to CH4198/84A priority patent/CH661272A5/fr
Priority to KR1019840005440A priority patent/KR910002838B1/ko
Priority to FR8413674A priority patent/FR2551756B1/fr
Priority to DE19843432985 priority patent/DE3432985A1/de
Publication of JPS6056979A publication Critical patent/JPS6056979A/ja
Publication of JPH0437833B2 publication Critical patent/JPH0437833B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP58166258A 1983-09-08 1983-09-08 ４，７−ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法 Granted JPS6056979A (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP58166258A JPS6056979A (ja) 1983-09-08 1983-09-08 ４，７−ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法
US06/641,822 US4562256A (en) 1983-09-08 1984-08-17 1,6-Dialkyl-3-substituted-4-nitrophenyl-4,7-dihydropyrazolo[3,4-b]pyridine-5-carboxylic acid esters
GB08421763A GB2146326B (en) 1983-09-08 1984-08-28 4,7-dihydropyrazolo(3,4-b)pyridine derivates
CH4198/84A CH661272A5 (fr) 1983-09-08 1984-09-03 Derives de 4,7-dihydropyrazolo (3,4-b)pyridine et composition pharmaceutique a action anti-hypertensive et de vasodilatation coronaire les renfermant.
KR1019840005440A KR910002838B1 (ko) 1983-09-08 1984-09-05 4.7-디히드로피라졸로[3,4-b]피리딘 유도체의 제조방법
FR8413674A FR2551756B1 (fr) 1983-09-08 1984-09-05 Derives de 4,7-dihydropyrazolo (3,4-b)pyridine et composition pharmaceutique a action anti-hypertensive et de vasodilatation coronaire les renfermant
DE19843432985 DE3432985A1 (de) 1983-09-08 1984-09-07 4,7-dihydropyrazolo(3,4-b)pyridin-derivate und ihre verwendung zur behandlung von erkrankungen des kreislaufsystems

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58166258A JPS6056979A (ja) 1983-09-08 1983-09-08 ４，７−ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法

Publications (2)

Publication Number Publication Date
JPS6056979A JPS6056979A (ja) 1985-04-02
JPH0437833B2 true JPH0437833B2 (en]) 1992-06-22

Family

ID=15828039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58166258A Granted JPS6056979A (ja) 1983-09-08 1983-09-08 ４，７−ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法

Country Status (7)

Country Link
US (1) US4562256A (en])
JP (1) JPS6056979A (en])
KR (1) KR910002838B1 (en])
CH (1) CH661272A5 (en])
DE (1) DE3432985A1 (en])
FR (1) FR2551756B1 (en])
GB (1) GB2146326B (en])

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873334A (en) * 1982-10-05 1989-10-10 Shionogi & Co., Ltd. 4,7-dihydropyrazolo(3,4-b) pyridine derivatives
JPS6210087A (ja) * 1985-07-03 1987-01-19 Shionogi & Co Ltd ４，７−ジヒドロチエノ〔２，３−ｂ〕ピリジン誘導体，その製造法および循環器系疾患治療剤
JP2005501800A (ja) * 2001-02-02 2005-01-20 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物およびその医薬用途
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857849A (en) * 1973-02-28 1974-12-31 Bayer Ag 2-amino-1,4-dihydropyridine derivatives
JPS5965089A (ja) * 1982-10-05 1984-04-13 Shionogi & Co Ltd ジヒドロピラゾロ〔３，４−ｂ〕ピリジン誘導体およびその製造法
JPS60197685A (ja) * 1984-03-19 1985-10-07 Shionogi & Co Ltd ４，７―ジヒドロピラゾロ［３，４―ｂ］ピリジン誘導体とその製造法
GR79111B (en]) * 1982-12-20 1984-10-02 Lepetit Spa

Also Published As

Publication number Publication date
CH661272A5 (fr) 1987-07-15
GB8421763D0 (en) 1984-10-03
JPS6056979A (ja) 1985-04-02
GB2146326B (en) 1987-01-14
KR910002838B1 (ko) 1991-05-06
GB2146326A (en) 1985-04-17
DE3432985A1 (de) 1985-03-28
KR850002095A (ko) 1985-05-06
DE3432985C2 (en]) 1993-09-16
FR2551756B1 (fr) 1987-10-02
FR2551756A1 (fr) 1985-03-15
US4562256A (en) 1985-12-31

Similar Documents

Publication Publication Date Title
JPS63290874A (ja) １，４−ジヒドロピリジンカルボン酸化合物の製造方法
JPH0542431B2 (en])
EP0586560A1 (en) Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
JPH036151B2 (en])
JPH05506249A (ja) ビスーベンゾシクロヘプタピペリジリデン、ピペリジンおよびピペラジン化合物、組成物および使用法
JPS60214778A (ja) Ν置換３，４−ジヒドロピリミジン誘導体ならびにその製造法および用途
JPH0688973B2 (ja) １，４−ジヒドロピリジン誘導体
JPH0437833B2 (en])
JPH0556358B2 (en])
EP0139221A2 (en) Substituted dihydroazepines useful as calcium channel blockers, methods for preparing and compositions containing the same
US4874773A (en) 3-Aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds, and pharmaceutical composition containing the same
JPH0692915A (ja) １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
EP0093945B1 (en) 1,4-dihydropyridine derivatives
PL106084B1 (pl) Sposob wytwarzania nowego estru izobutylowego kwasu 2,6-dwumetylo-3-metoksykarbonylo-4-/2'-nitrofenylo/1,4-dwuwodoropirydyno-5-karboksylowego
JPS6024794B2 (ja) オキサジアゾロピリミジン誘導体
JPH0686436B2 (ja) 新規ヒダントイン誘導体及び該化合物を含有する医薬組成物
CA1282411C (en) 1,4,5,6,7,8-hexahydroquinoline compounds
EP0157260B1 (en) 4,7-dihydropyrazolo(3,4-b)pyridine derivatives
JP2528899B2 (ja) ３−アミノカルボニル−１，４−ジヒドロピリジン−５−カルボン酸エステル誘導体
EP0220917B1 (en) 1,4-dihydropyridine pharmaceutical derivatives and their salts, and the preparation thereof
JP3999861B2 (ja) 新規ピリダジン誘導体及びこれを有効成分とする医薬
JPS58201764A (ja) ジヒドロピリジン誘導体
JPS6317068B2 (en])
SE439164B (sv) 1,1-disubstituerade oktahydro-indolo(2,3-a)kinoliziner och farmaceutisk beredning innehallande dem
IL91552A (en) Antipsychotic 4-[4-(3-benzisothiazolyl)-1- piperazinyl] butyl bridged bicyclic imides and pharmaceutical compositions containing them